American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 1028-1032 , December 2007

Treatment of Idiopathic Membranous Nephropathy With the Herb Astragalus membranaceus

  • Mohammed S. Ahmed, DO

      Affiliations

    • Department of Medicine, Loyola University Medical Center, Maywood, IL
    • ,
  • Susan H. Hou, MD

      Affiliations

    • Department of Medicine, Loyola University Medical Center, Maywood, IL
    • ,
  • M. Carol Battaglia, BSN

      Affiliations

    • Department of Medicine, Loyola University Medical Center, Maywood, IL
    • ,
  • Maria M. Picken, MD, PhD

      Affiliations

    • Department of Pathology, Loyola University Medical Center, Maywood, IL.
    • ,
  • David J. Leehey, MD

      Affiliations

    • Department of Medicine, Loyola University Medical Center, Maywood, IL
    • Corresponding Author InformationAddress correspondence to David J. Leehey, MD, Loyola University Medical Center, Department of Nephrology and Hypertension, Bldg 102, Rm 3661, 2160 S First Ave, Maywood, IL 60153.

Received 10 January 2007 ,Accepted 5 July 2007.

References 

  1. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25:862–875
  2. Honkanen E, Tornroth T, Gronhagen-Riska C. Natural history, clinical course and morphological evolution of membranous nephropathy. Nephrol Dial Transplant. 1992;7(suppl 1):S35–S41
  3. Falk RJ, Jennette JC, Nachman PH. Primary glomerular disease. In:  Brenner BM editors. Brenner & Rector’s The Kidney. ed 7. Philadelphia, PA: Saunders; 2004;p. 1293–1380
  4. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy. Am J Kidney Dis. 2005;46:1012–1029
  5. Peng A, Gu Y, Lin SY. Herbal treatment for renal diseases. Ann Acad Med Singapore. 2005;34:44–51
  6. Cheng KT, Tsay HS, Chen CF, Chou TW. Determination of the components in a Chinese prescription, yu-ping-feng san, by RAPD analysis. Planta Med. 1998;64:563–565
  7. Wang YP, Li XY, Song CQ, Hu ZB. Effect of astragaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice. Acta Pharmacol Sin. 2002;23:263–266
  8. Zhao ZX. Effects of Astragalus membranaceus and Tripterygium hypglancum on natural killer cell activity of peripheral blood mononuclear cells in systemic lupus erythematosus. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1992;12:669–671
  9. Shi JF, Zhu HW, Zhang C, Bian F, Shan JP, Lu WI. Therapeutic effect of Astragalus in patients with chronic glomerulonephritis. Acta Univ Medicinalis Secondae Shanghai. 2002;22:245–248
  10. Cavallo T. Membranous nephropathy (Insights from Heymann nephritis). Am J Pathol. 1994;144:651–658
  11. Quigg RJ, Holers VM, Morgan BP, Sneed AE. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol. 1995;154:3437–3443
  12. Nangaku M, Quigg RJ, Shankland SJ, Okada N, Johnson RJ, Couser WG. Overexpression of Crry protects mesangial cells from complement-mediated injury. J Am Soc Nephrol. 1997;8:223–233
  13. Cai Q, Li X, Wang H. Astragali and Angelica protect the kidney against ischemia and reperfusion injury and accelerate recovery. Chin Med J (Engl). 2001;114:119–123
  14. Thurman JM, Ljubanovic D, Royer PA, et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest. 2006;116:357–368
  15. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33:1389–1401

 Originally published online as doi:10.1053/j.ajkd.2007.07.032 on October 16, 2007.

PII: S0272-6386(07)01152-3

doi: 10.1053/j.ajkd.2007.07.032

American Journal of Kidney Diseases
Volume 50, Issue 6 , Pages 1028-1032 , December 2007

Article Tools

* Image Usage & Resolution